Pool Global Partners

Oncoustics develops AI-enhanced ultrasound technology to analyze raw ultrasound signals from handheld devices, enabling rapid differentiation between healthy and diseased tissue. The approach generates novel acoustic biomarkers and supports non-invasive surveillance, diagnostics, and treatment monitoring for diseases with high unmet clinical needs. The company aims to improve clinical workflow productivity and has pursued regulatory pathways such as FDA Breakthrough Device designation for its OnX liver fibrosis detection, with 510(k) submission in progress, and plans for follow-on liver and other organ indications including prostate, kidney, breast and thyroid diseases and cancers.

Modl.ai specializes in AI-driven gaming technology that streamlines game development and enhances player engagement globally.

Prescryptive Health, Inc. is a digital health company that operates a prescription benefits platform aimed at enhancing the accessibility and affordability of medications for both payers and patients. Established in 2017 and based in Redmond, Washington, the company provides services that include analyzing current plan designs, recommending new plans, and facilitating member enrollment. Its platform empowers users by offering direct access to market pricing, unbiased information, and real-time cost insights regarding prescribed treatments. This includes details on insurance coverage, out-of-pocket expenses, and available lower-cost alternatives. Prescryptive Health serves a diverse range of clients, including employers, health plans, providers, pharmacies, and pharmaceutical companies, with the goal of democratizing the prescription drug market.

Acorn Biolabs, Inc. is a biotechnology company based in Toronto, Canada, founded in 2017. It specializes in providing a take-home service for the cryopreservation of human cells, focusing on young cell preservation to facilitate future regenerative medical treatments. The company employs a non-invasive, follicle-based cell collection method, allowing individuals to collect and preserve their healthy young cells for potential use in gene therapies, stem cell therapeutics, tissue engineering, and organ regeneration. Acorn Biolabs offers its services directly to consumers, with options for at-home and in-clinic cell collection. The company also has established partnerships with a network of clinics and pharmacies across Canada to enhance accessibility to its innovative services.

RentLogic is a New York-based company established in 2013, specializing in evaluating and grading multi-family residential buildings in New York City. It uses physical inspections and objective health and safety standards to assign grades of A, B, C, or F to approximately 1.1 million apartment buildings. RentLogic's methodology is developed collaboratively with stakeholders from various housing sectors, ensuring fairness, credibility, and objectivity. The company connects building owners with residents through its platform, recognizing those who maintain high-quality buildings and assisting tenants in navigating the rental market.

Tread, Inc. is a Toronto-based company that specializes in developing a platform for managing construction equipment services. Founded in 2016, Tread's software facilitates interaction among contractors, brokers, and operators, allowing them to operate as if they are part of the same fleet. The platform leverages data analytics to optimize equipment usage, helping construction companies to record and measure usage in real-time. By providing insights into equipment operations, Tread enables clients to achieve data-driven improvements and reduce costs associated with construction projects.

MIMOSA Diagnostics Inc. is a Toronto-based company founded in 2016 that specializes in developing innovative medical devices for tissue assessment. The company has created the MIMOSA Pro, a handheld device that utilizes near-infrared light technology to non-invasively evaluate tissue health, enabling both patients and caregivers to monitor critical health indicators. This device is particularly beneficial for diabetes patients, as it allows for real-time assessments of foot health, which is essential in preventing complications. MIMOSA Diagnostics aims to enhance clinical decision-making by providing healthcare professionals with the capability to visualize physiological biomarkers beneath the skin's surface, delivering accurate information that can lead to improved treatment outcomes, irrespective of skin color.

Plantiga Technologies Inc. is a Vancouver-based company that specializes in biometric sensing technology for footwear. Founded in 2006, it focuses on human movement intelligence, offering deep insights into health through the analysis of movement patterns. The company's platform aims to optimize health, prevent injuries, and monitor recovery by detecting changes in functional movement that are often imperceptible to the naked eye. Plantiga's innovative foot-strike analytics technology combines the rigor of human performance analysis with the immediacy of wearable devices, allowing users to evaluate athletic performance, health, and productivity effectively.

InnerSpace Technologies Inc., established in 2014 and headquartered in Toronto, Canada, specializes in indoor mapping and navigation solutions. It offers a turnkey platform that automatically generates maps and locates people and objects within indoor spaces using advanced mapping technology, smartphone-compatible sensors, and machine learning. The company's location-as-a-service provides contextual maps and positioning data on a subscription basis, catering to both enterprise and consumer needs. With a global presence, InnerSpace serves clients primarily in the United States, Europe, Asia, and Canada, helping them make informed decisions about space utilization and corporate real estate.

Oncoustics develops AI-enhanced ultrasound technology to analyze raw ultrasound signals from handheld devices, enabling rapid differentiation between healthy and diseased tissue. The approach generates novel acoustic biomarkers and supports non-invasive surveillance, diagnostics, and treatment monitoring for diseases with high unmet clinical needs. The company aims to improve clinical workflow productivity and has pursued regulatory pathways such as FDA Breakthrough Device designation for its OnX liver fibrosis detection, with 510(k) submission in progress, and plans for follow-on liver and other organ indications including prostate, kidney, breast and thyroid diseases and cancers.

Miovision Technologies Inc., established in 2005, specializes in traffic data collection and management solutions. Based in Kitchener, Canada, with an additional office in Cologne, Germany, the company serves traffic data collection firms, engineering firms, and government agencies globally. Miovision offers a suite of products, including Miovision Central for project management, Scout devices for data collection, and Miovision Traffic Data for analysis. Additionally, they provide tools to monitor and manage traffic signal performance, and Teal, a platform for goal tracking. Their solutions leverage computer vision and AI to help cities optimize traffic flow, reduce environmental impacts, and enhance transportation experiences for all users.